Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVK36Q)

Drug Name
Hematoporphyrin Drug Info
Synonyms
1,3,5,8-Tetramethyl-2,4-bis(alpha-hydroxyethyl)prophine-6,7-dipropionic acid; 2,18-Porphinedipropionic acid, 7,12-bis(1-hydroxyethyl)-3,8,13,17-tetramethyl-; 21H,23H-Porphine-2,18-dipropanoic acid, 7,12-bis(1-hydroxyethyl); 7,12-Bis(1-hydroxyethyl)-3,8,13,17-tetramethyl-21H,23H-porphine-2,18-dipropanoic acid; HEMATOPORPHYRIN; HP; HP (VAN); Haematoporphyrin; Hematoporphyrin I; Hematoporphyrin IX; ISOHEMATOPORPHYRIN IX; NSC 267084; NSC 59265; NSC59265; Photodyn
Therapeutic Class
Antiasthenia Agents
Cross-matching ID
PubChem CID
11103
ChEBI ID
ChEBI:36162
CAS Number
CAS 14459-29-1
TTD Drug ID
DMVK36Q
VARIDT Drug ID
DR00336

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTP
Drug Status:
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Transported By Breast cancer resistance protein (ABCG2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [2]
Methotrexate DM2TEOL Anterior urethra cancer Approved [3]
Folic Acid DMEMBJC Colorectal carcinoma Approved [4]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [5]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [6]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [7]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [8]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [7]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [9]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [1]

References

1 Cellular phototoxicity evoked through the inhibition of human ABC transporter ABCG2 by cyclin-dependent kinase inhibitors in vitro. Pharm Res. 2009 Feb;26(2):449-58.
2 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
3 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
4 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
5 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
6 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
7 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
8 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
9 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
10 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.